Chir-258
Gastrinoma
Academic and Community Cancer Research UnitedPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Gastrinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Emory University | Phase 2 | B |
Omeprazole National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | B |
(+)-VINCRISTINE Shaheen Shagufta | Phase 2 | B |
Gefetinib National Cancer Institute (NCI) | Phase 2 | B |
Regorafenib University of Southern California | Phase 2 | B |
View all 17 →
Same molecule, other indications
Chir-258 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →